Licensing

Asian currency
Investment
Eyes on Asia: Ascentage’s IPO, Arrivent & Lepu, Sanofi approval, and moreEyes on Asia: Ascentage’s IPO, Arrivent & Lepu, Sanofi approval, and more

BioXconomy presents the Asia biopharma and healthcare dealmaking and financing news for the week ending 2 February.

byMillie Nelson, Editor
Feb 3, 2025
|
1 Min Read
Monika Paulė (Caszyme) and Dr Avencia Sánchez-Mejías (Integra Therapeutics) at BIO-Europe in Stockholm
Partnering
Partnerships underpin the CRISPR revolution, says Caszyme CEOPartnerships underpin the CRISPR revolution, says Caszyme CEO
byMillie Nelson
Jan 30, 2025
1 Min Read
Asia on a world globe
Innovation
Eyes on Asia: AZ C-suite, Verdiva and Sciwind, Korea and China at JPMEyes on Asia: AZ C-suite, Verdiva and Sciwind, Korea and China at JPM
byDan Stanton
Jan 21, 2025
1 Min Read
magnifying glass focused on China flag
Innovation
China biopharma development still hot & still expanding its reachChina biopharma development still hot & still expanding its reach
byRichard Daverman
Jan 21, 2025
1 Min Read
Image of China banknotes with a magnifying glass indicating dealmaking in Asia
Hubs
Eyes on Asia: BIOSECURE, Merck & Hansoh, Roche adds ADC, and SamsungEyes on Asia: BIOSECURE, Merck & Hansoh, Roche adds ADC, and Samsung
byDan Stanton
Jan 8, 2025
1 Min Read
Currency
Investment
Eyes on Asia: Merck and BioNTech land Chinese bispecificsEyes on Asia: Merck and BioNTech land Chinese bispecifics
byRichard Daverman
Dec 4, 2024
1 Min Read
The ELA'S 2024
Innovation
LSX awards the crème de la crème of dealmaking
LSX awards the crème de la crème of dealmaking
Dec 3, 2024
|
1 Min Read
byMillie Nelson, Editor
Partnering
Novo’s hunt for genetic med tech drove $600m NanoVation pact
Novo’s hunt for genetic med tech drove $600m NanoVation pact
Oct 1, 2024
|
1 Min Read
byMillie Nelson, Editor
Oncology
Partnering
Bayer and NextRNA: One partnership, two oncology programs
Bayer and NextRNA: One partnership, two oncology programs
Sep 25, 2024
|
1 Min Read
byMillie Nelson, Editor
Hubs
Eyes on Asia: Shinyaku’s $735m DMD deal, Kite turns back in China, and more
Shinyaku’s $735m DMD deal, Kite turns back in China, and more
Sep 23, 2024
|
1 Min Read
byRichard Daverman, Editor
Chinese flag — Photo
Investment
China biopharma faces a pause; how bad is it?
China biopharma mid-2023 market summary
Sep 21, 2024
|
1 Min Read
byRichard Daverman, Editor
Illustration, Science word. Business concept for Study of physical world structure behavior Experimental research — Illustration
Innovation
European drug discovery and development players showcase their science at BIO-Europe 2023
European drug discovery and development players showcase their science
Sep 21, 2024
|
1 Min Read
Investment
Eyes on Asia: Eisai $1.5bn pact, OcuMension & Alcon, TYK IPO and more
Eyes on Asia: Eisai $1.5bn pact, OcuMension & Alcon, TYK IPO and more
Sep 18, 2024
|
1 Min Read
byRichard Daverman, Editor
Partnering
Top five Asia biopharma deals: August 2024
Asia biopharma deals: August 2024
Sep 15, 2024
|
1 Min Read
byRichard Daverman, Editor
Innovation
Eyes on Asia: UCB portfolio sale, Navigator bags $100m, Bora bulks out CDMO biz
Eyes on Asia: UCB portfolio sale, Navigator bags $100m, Bora bulks out CDMO biz
Sep 1, 2024
|
1 Min Read
byRichard Daverman, Editor
Investment
Eyes on Asia: Mulititude out licenses, Huadong bulks up Abs, Merck and Kelun
Eyes on Asia: Multitude out licenses, Huadong bulks up Abs, Merck and Kelun
Aug 25, 2024
|
1 Min Read
byRichard Daverman, Editor
CEO of Poseida, Kristin Yarema
Business Strategy
Poseida: New CEO, same passion for allogeneic therapies
Poseida: New CEO, same passion for allogeneic therapies
Feb 26, 2024
|
1 Min Read
byMillie Nelson, Editor

BIO-EUROPE COVERAGE

Novo Nordisk sign
Business Strategy
Lessons and blessings: The Novo Nordisk way
Lessons and blessings: The Novo Nordisk way
Michael May, PhD, President, CCRM discusses Canada as a place for life sciences in this video.
Hubs
Bridging AI & Life Sciences, Why Investing in Canada Should Be Your Next Move
Bridging AI & Life Sciences, Why Investing in Canada Should Be Your Next Move
Shaking hands
Partnering
Picky pharma prone to better proven partners amid dealmaking downturn
Picky pharma prone to better proven partners amid dealmaking downturn
Hervé Ansanay, Biotech Alliance Manager, discusses the features of the RESEAU SATT - SATT NETWORK
Sponsored Content
RESEAU SATT, the Best of French Deep Tech
RESEAU SATT, the Best of French Deep Tech

Latest

Male being kept up at night and unable to sleep
Investment
Interest rates, IPOs, China, or Trump: What’s keeping investors up at night?
Interest rates, IPOs, China, or Trump: What’s keeping investors up at night?
Asia map on the globe
Hubs
Eyes on Asia: Bain Capital buys MTPC, Merck & Co. halts HPV vax, and Illumina
Eyes on Asia: Bain Capital buys MTPC, Merck & Co. halts HPV vax, and Illumina
Francesco De Rubertis, co-founder and partner at Medicxi (left) and Graziano Seghezzi, managing partner at Sofinnova Partners (right).
Investment
Sofinnova and Medicxi talk M&A, patent cliffs, and China
Sofinnova and Medicxi talk M&A, patent cliffs, and China
Mar 17 - Mar 19, 2025
Europe's Largest Springtime Biotech Partnering Event
REGISTER
Subscribe to Our Newsletters
Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.
Stay Updated